Delivering on the promise of biochemicals at scale
In a world demanding real change to limit the climate crisis, we are still miles away from replacing the toxic fossil-based chemicals used everywhere in everyday life.
Until now… Circa is one of the very few businesses with the technology to produce sustainable alternatives at scale.
Sustainability is firmly on the agenda of all responsible companies, and with corporate responsibilities extending deep into supply chains, the chemical building blocks of everyday products are under increasing scrutiny. However, there are opportunities for those with the foresight to act.
Circa is enabling the transition to better, greener, safer chemistry. We have made the breakthrough – now we need you.
We need change.
For all of us.
Find out more about replacing NMP with our bio-based solvent Cyrene™
In order to further our efforts in sustainable chemistry, we have been working with Circa Group for incorporating their key building block Levoglucosenone in the manufacturing of our new medicines. Merck believes that LGO and its derivatives are a green, versatile and sustainable platform for the synthesis of pharmaceuticals. Merck also has found that these derivatives will help us make these new medicines at a competitive price compared to that manufactured using traditional chemistry techniques.
Prashant S. Savle, Ph. D — Director Global Procurement, Merck Sharp & Dohme Corp.
CIRCA’S LEVOGLUCOSENONE DERIVATIVE USED IN AWARD WINNING MANUFACTURING METHOD FOR INVESTIGATIONAL CANCER DRUG
The ReSolute plant
With the support of the EU Horizon 2020 research and innovation programme Circa’s ReSolute* plant will scale-up Cyrene™ production to 1,000 tonnes in 2023.
Repurposing a coal-fired power station in the North East of France, Circa is helping to create a lower carbon economy that provides skilled jobs in clean technologies.
ReSolute is the green deal in motion.
Executive Director, Circular Bio-based Europe Joint Undertaking
*This project has received funding from the Bio-based Industries Joint Undertaking (JU) under grant agreement No 887674. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and the Bio-based Industries Consortium.